Diagnostics
Filter News
Found 6,193 articles
-
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma
2/11/2022
Inivata, a leader in liquid biopsy, announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.
-
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
2/11/2022
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma.
-
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2/10/2022
GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, announced its financial results for the second quarter ended December 31, 2021 and provided a recent business update.
-
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference
2/10/2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference.
-
Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital
2/10/2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), announced today that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building.
-
Day Zero Diagnostics Announces Completion of $21M Financing
2/9/2022
Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced the completion of a $21M venture equity financing.
-
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
2/9/2022
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Dr. Rainer Metzger to its Strategic Advisory Board.
-
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/9/2022
Biodesix, Inc. announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022.
-
Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank
2/8/2022
Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. and Silicon Valley Bank .
-
Quotient Limited Reports Third Quarter Fiscal 2022 Results and Provides Business Update
2/8/2022
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its third quarter fiscal 2022 key financial results and furnished an update on recent business developments.
-
Seno Medical’s Imagio® Breast Imaging System Named Science and Medical Category Finalist in 2022 Edison Awards Program
2/8/2022
Seno Medical’s Imagio® Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.
-
Exact Sciences schedules fourth quarter 2021 earnings call
2/8/2022
Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022.
-
Sera Prognostics To Present At Upcoming February 2022 Investor Conferences
2/7/2022
Sera Prognostics Inc. announced that the company will present at the upcoming virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT.
-
Devyser acquires Italian SmartSeq and strengthens position in genetic data analysis
2/7/2022
Devyser Diagnostics AB, a Swedish molecular diagnostics company, announced that the company has utilized an option to acquire all of the remaining shares in the associated company SmartSeq S.r.l.
-
Biovica Provides Time-Plan for FDA Submission
2/7/2022
Biovica, active in cancer diagnostics, announces that it has received full feedback from the FDA on its updated 510-application enabling a clear plan for the submission process.
-
Late-breaking Data Presented at SMFM 2022 Annual Meeting Shows The Mirvie RNA Platform is First to Reveal The Underlying Biology of Preterm Birth
2/4/2022
Mirvie, a pioneer in predicting unexpected pregnancy complications, announced data presented at the Society for Maternal-Fetal Medicine 42nd Annual Pregnancy Meeting demonstrates the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.
-
T2 Biosystems Reports Granting of Inducement Award - Feb 04, 2022
2/4/2022
T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to eighteen new employees.
-
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
2/4/2022
Mainz Biomed N.V. announced it has commenced ColoFuture, an international clinical study to evaluate the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer which is being commercialized across Europe.
-
Up to 40% of AD patients were found to have Lewy Bodies in their brain after succumbing to the disease.
-
MRM Proteomics, Inc. and Agilent Technologies, Inc.: A Collaboration for Progress
2/3/2022
MRM Proteomics, Inc. and Agilent Technologies Inc. are excited to announce their new co-marketing agreement aimed to further advance the capabilities of quantitative proteomic applications and thereby help the scientific community make impactful, novel scientific discoveries.